Prestige Consumer Healthcare Inc.
No SEC Form 4 filings for $PBH in the last 30 days.
See all $PBH insider activity →Prestige Brand Holdings is recalling 39,060 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops due to potential contamination. The FDA classified this as a Class II recall, indicating temporary health risks. The affected product has lot code 2552A and expires on September 30, 2027. Prestige Brands' stock (PBH) is up 1.56%.
Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pbh-20260810 0001295947 false 0001295947 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of ea
Prestige Consumer Healthcare (NYSE:PBH) reported Q1 fiscal 2027 sales of $265.7M (+6.5% YoY) and adjusted diluted EPS of $0.98. The company closed Breathe Right (June 12) and LaCorium Health (July 1), adding about $240M annualized revenue and raising FY sales guidance to $1.29B-$1.315B and adjusted EPS to $4.55-$4.65. Clear Eyes faces supply constraints; acquisitions were funded with new debt.
Over the past 7 days, alphai's AI scored 1 news story mentioning PBH (Prestige Consumer Healthcare Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent PBH coverage spans corporate actions, mergers & acquisitions and earnings.
Recall may pressure PBH's stock and raise safety concerns for its consumer health portfolio.
Board/officer transition filing may affect near-term operational continuity and internal succession expectations, but provides no performance or guidance details.
Near-term risk is margin and organic growth volatility from Clear Eyes supply constraints and higher interest/amortization from new debt, offset by guidance lift from acquisitions.
The call provides a near-term earnings and cash-flow snapshot plus concrete acquisition and Clear Eyes recovery plans that can drive sentiment and positioning.
The earnings and guidance update, plus a dividend declaration and asset sale, create multiple near-term catalysts for PBH’s valuation and positioning.
alphai scores every news story that mentions PBH with an AI model for sentiment and relevance, and aggregates insider trades from Prestige Consumer Healthcare Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Prestige Brand Holdings is recalling 39,060 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops due to potential contamination. The FDA classified this as a Class II recall, indicating temporary health risks. The affected product has lot code 2552A and expires on September 30, 2027. Prestige Brands' stock (PBH) is up 1.56%.
1 min readPrestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pbh-20260810 0001295947 false 0001295947 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of ea
2 min readPrestige Consumer Healthcare (NYSE:PBH) reported Q1 fiscal 2027 sales of $265.7M (+6.5% YoY) and adjusted diluted EPS of $0.98. The company closed Breathe Right (June 12) and LaCorium Health (July 1), adding about $240M annualized revenue and raising FY sales guidance to $1.29B-$1.315B and adjusted EPS to $4.55-$4.65. Clear Eyes faces supply constraints; acquisitions were funded with new debt.
6 min readPrestige Consumer Healthcare (PBH) reported Q1 fiscal 2027 sales of about $266 million, up 6.5%, with growth led by GI brands such as Dramamine and Fleet and skin care brands including Compound W. Adjusted EPS rose to $0.98 and adjusted free cash flow reached $83.7 million. PBH also completed acquisitions of the Breathe Right portfolio (closed June 12) and LaCorium (July 1).
10 min readPremium Brands Holdings (TSX: PBH) reported record Q2 2026 results. Revenue rose to $2.4B, up 26.3% year over year, with 7.5% organic sales growth. Adjusted EBITDA from continuing operations increased to $225.0M and adjusted EPS to $1.53. The company declared a $0.85 dividend for Q3 and revised 2026 guidance due to delayed promotions/new product launches.
6 min readPrestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991fy27-q1earningsr.htm EX-99.1 Document Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results • Q1 Revenue of $265.7 million up 6.5% versus prior year • Q1 Organic sales growth of 3.2%, exceeding expectations • Q1 Diluted EPS o
6 min readPrestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 tm2620415d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 INDENTURE Dated as of July 15, 2026 Among PRESTIGE BRANDS, INC., as the Issuer, the Guarantors from time to time party hereto and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee 6.250% SENIOR NOTES DUE 2034 TABLE OF
4 min readPrestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-99.1 2 exhibit991prestige-launchp.htm EX-99.1 Document Exhibit 99.1 Prestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior Notes July 6, 2026 TARRYTOWN, N.Y., July 6 , 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) a
4 min readPrestige Consumer Healthcare (NYSE:PBH) said it completed on June 15 the $1.045 billion acquisition of the Breathe Right brand and other brands from Foundation Consumer Healthcare. PBH expects the deal to expand its OTC portfolio; Breathe Right is projected to generate about $200M revenue and $95M core profit in 2025.
3 min readThe article says Alphabet’s inclusion in the Dow and Berkshire Hathaway’s increased holding drew attention, but focuses on Prestige Consumer Healthcare (PBH). It reports PBH closed a $1.045B acquisition of Breathe Right and other OTC brands on June 15, adding ~$200M annual revenue and ~$95M EBITDA, and notes net leverage ~4.0x at closing.
6 min read
